H.C. Wainwright Maintains a Buy Rating on Avrobio Inc (AVRO)

By Ryan Adsit

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Avrobio Inc (AVROResearch Report) today and set a price target of $35. The company’s shares closed yesterday at $20.04.

According to TipRanks.com, Chattopadhyay has 0 stars on 0-5 star ranking scale with an average return of -2.9% and a 39.8% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.

Avrobio Inc has an analyst consensus of Strong Buy, with a price target consensus of $31.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $53.70 and a one-year low of $11.85. Currently, Avrobio Inc has an average volume of 322K.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AVRO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network.